Hungry rats in Skinner boxes were trained to select the right or left lever as correct as a function of the presence of a tone or light stimulus, respectively. Correct responses produced liquid food rewards. Acute intraperitoneal administration of d-amphetamine or phenobarbital did not affect accuracy of performance, but decreased the percent trials attempted and lengthened response times as a function of increasing doses. The mean extra responses during the delay intervals generally decreased under phenobarbital and increased under d-amphetamine. Juvenile baboons were trained to respond on a delayed match-to-sample task in order to obtain banana pellet rewards. Acute intramuscular administration of phenobarbital produced a dose-related increase in errors, a decrease in mean extra responses and an increase in response times. A slight reduction in the percent trials attempted occurred only at the highest dose of the drug. Acute intramuscular d-amphetamine did not increase errors even at dose levels that increased reaction times, decreased extra responses and reduced the percent trials attempted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0091-3057(83)90259-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer.
Int J Breast Cancer
January 2025
Department of Hematology and Oncology, Houston Methodist Dr Mary and Ron Neal Cancer Center, Houston, Texas, USA.
This study evaluates the effects of hydroxytyrosol (HT), a component of olive oil, on mammographic breast density reduction. We explored effects of HT on Wnt -catenin and other pathways involved in cancer stem cell renewal, DNA repair, cell proliferation, and differentiation. Twenty-five milligrams per day oral dose of HT was given for 12 months in pre- and postmenopausal women at increased risk of breast cancer.
View Article and Find Full Text PDFAnalytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.
J Mol Diagn
February 2025
Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
This study demonstrates the analytical and clinical validity of the approved (United States and Japan) plasma-based Guardant360 companion diagnostic (CDx) test for selecting patients with human epidermal growth factor receptor 2 (HER2 [ERBB2])-mutated (HER2m) non-small-cell lung cancer (NSCLC) for trastuzumab deruxtecan (T-DXd) treatment. Concordance between the Guardant360 CDx test and the plasma-based AVENIO ctDNA Expanded Kit Assay (AVENIO), as well as the tissue-based clinical trial assays (CTAs) was investigated. Clinical utility was assessed by comparing T-DXd clinical efficacy results of patients in DESTINY-Lung01/02 who tested positive for HER2 mutations using the Guardant360 CDx test to benchmark efficacy results from DESTINY-Lung01/02.
View Article and Find Full Text PDFImpact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.
JACC Adv
February 2025
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.
Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.
Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.
Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes.
BJUI Compass
January 2025
Department of Urology, Institute of Urologic Oncology UCLA Los Angeles California USA.
Objectives: The aim of this study is to evaluate new software (Unfold AI) in the estimation of prostate tumour volume (TV) and prediction of focal therapy outcomes.
Subjects/patients And Methods: Subjects were 204 men with prostate cancer (PCa) of grade groups 2-4 (GG ≥ 2), who were enrolled in a trial of partial gland cryoablation (PGA) at UCLA from 2017 to 2022. Magnetic resonance imaging (MRI)-guided biopsy (MRGB) was performed at diagnosis and at 6 and 18 months following PGA.
Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background And Purpose: The randomised clinical trial KEYNOTE-048 has demonstrated a significant increase in survival for patients with head and neck cancer treated with pembrolizumab with or without chemotherapy. The purpose of the present retrospective study was to investigate whether survival in a group of consecutive patients treated at our department was comparable to the results from KEYNOTE-048.
Patients/material And Methods: Seventy-six patients initiated treatment with pembrolizumab ± platinum/5-FU between July 2020 and May 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!